Recently, PARx expanded our partnership with ZappRx, a healthcare technology company that reduces the administrative burden associated with prescribing specialty medications. As of June 2018, ZappRx users – which range from large academic medical centers to small, independent physician practices – can access PARx Solutions’ prescription prior authorization services across all treatment areas supported on the ZappRx platform. This is especially good news for practices in Gastroenterology, Rheumatology, Cardiology, and Neurology, broadening their ability to significantly shorten the prior authorization timeline. ZappRx leverages our PASS (prior authorization support system) to alleviate the administrative burden for medical practices.
As I noted in the announcement of this expanded partnership, since the beginning, ZappRx and PARx Solutions have been very complementary. We believe that ZappRx offers specialty drug prescribers a comprehensive solution that makes it dramatically easier for physicians to combat and treat complex diseases. Together, we have been tremendously successful in the past 18 months within the Pulmonary Arterial Hypertension (PAH), Idiopathic Pulmonary Fibrosis, and Cystic Fibrosis (CF) therapeutic categories, adding support this year for Congestive Heart Failure and Hyperlipidemia. We are excited to extend our joint solutions into new therapeutic categories, which will immediately and dramatically increase the number of lives we can positively impact.
And it’s already working: according to a ZappRx’s pre-implementation survey results, physicians who prescribed specialty drugs experienced PA approval rates below 75 percent before using the integrated ZappRx -PARx approach, In contrast, the ZappRx-PARx solution has produced approval rates of 95 percent, with approvals secured in a matter of days, not weeks, even for complex conditions such as PAH.
At a recent launch of the ZappRx Platform at a prestigious academic medical center, prescribers were thrilled to have the first PA submitted through the Platform approved the same afternoon. ‘The clinical staff was so surprised at the quick turnaround, that they actually reached out to our team to see if we were playing a joke,’ said Karen Tirozzi, Vice President of Solutions at ZappRx. PARx is excited about continuing to expand our partnership with ZappRx and look forward to providing PA support services to new health care organizations and physicians who choose the ZappRx platform for their specialty drug prescribing support.